Opin vísindi

Fletta eftir höfundi "Ørnbjerg, Lykke M"

Fletta eftir höfundi "Ørnbjerg, Lykke M"

Röðun: Raða: Niðurstöður:

  • Icon
    Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor : results from 13 European registries 
    Linde, Louise; Ørnbjerg, Lykke M; Georgiadis, Stylianos; Rasmussen, Simon H; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Di Giuseppe, Daniela; Wallman, Johan K; Guðbjörnsson, Björn; Löve, Þorvarður Jón; Nordström, Dan C; Yli-Kerttula, Timo; Nekvindová, Lucie; Vencovský, Jiří; Iannone, Florenzo; Cauli, Alberto; Loft, Anne Gitte; Glintborg, Bente; Laas, Karin; Rotar, Ziga; Tomšič, Matija; Macfarlane, Gary J; Möller, Burkhard; van de Sande, Marleen; Codreanu, Catalin; Nissen, Michael J; Birlik, Merih; Erten, Sukran; Santos, Maria J; Vieira-Sousa, Elsa; Hetland, Merete L; Østergaard, Mikkel (2023-06-14)
    OBJECTIVES: In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and ...
  • Icon
    Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries 
    Michelsen, Brigitte; Georgiadis, Stylianos; Di Giuseppe, Daniela; Loft, Anne G.; Nissen, Michael J.; Iannone, Florenzo; Pombo-Suarez, Manuel; Mann, Herman; Rotar, Ziga; Eklund, Kari K.; Kvien, Tore K.; Santos, Maria J.; Guðbjörnsson, Björn; Codreanu, Catalin; Yilmaz, Sema; Wallman, Johan K.; Brahe, Cecilie H.; Möller, Burkhard; Favalli, Ennio G.; Sánchez-Piedra, Carlos; Nekvindova, Lucie; Tomsic, Matija; Trokovic, Nina; Kristianslund, Eirik K.; Santos, Helena; Löve, Þorvarður Jón; Ionescu, Ruxandra; Pehlivan, Yavuz; Jones, Gareth T.; van der Horst-Bruinsma, Irene; Ørnbjerg, Lykke M.; Østergaard, Mikkel; Hetland, Merete L. (2022-04-29)
    Objective: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the ...